Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

7.50USD
18 Oct 2019
Change (% chg)

$-0.27 (-3.47%)
Prev Close
$7.77
Open
$7.66
Day's High
$7.88
Day's Low
$7.41
Volume
4,120,261
Avg. Vol
3,757,109
52-wk High
$23.97
52-wk Low
$6.07

Latest Key Developments (Source: Significant Developments)

UK's MHRA Says Teva UK Recalling Some Batches Of Ranitidine
Thursday, 17 Oct 2019 

Oct 17 (Reuters) - UK's MHRA::UK'S MHRA - ISSUED ALERT TO HEALTHCARE PROFESSIONALS, AS TEVA UK LTD IS RECALLING ALL UNEXPIRED STOCK OF CERTAIN BATCHES OF 2 TYPES OF RANITIDINE.UK'S MHRA - 2 PRODUCTS AFFECTED BY TEVA UK RECALL ARE RANITIDINE EFFERVESCENT TABLETS 150 MICROGRAMS AND 300 MICROGRAMS.UK'S MHRA - TEVA UK RECALL IS PRECAUTIONARY MEASURE DUE TO POSSIBLE CONTAMINATION OF ACTIVE SUBSTANCE IN ZANTAC, RANITIDINE WITH IMPURITY CALLED NDMA.UK'S MHRA - ON TEVA UK LTD'S RANITIDINE RECALL, ALL REMAINING STOCK SHOULD BE QUARANTINED AND RETURNED WITHOUT DELAY TO THE SUPPLIER.UK'S MHRA - HEALTHCARE PROFESSIONALS HAVE BEEN TOLD TO STOP SUPPLYING THE TWO RANITIDINE PRODUCTS IMMEDIATELY.  Full Article

U.S. Drug Companies Pursuing $50 Bln Settlement Of Opioid Cases- NYT
Thursday, 17 Oct 2019 

Oct 16 (Reuters) - :U.S. DRUG COMPANIES PURSUING $50 BILLION SETTLEMENT OF OPIOID CASES - NYT.  Full Article

Intercure Says Unit Canndoc Entered Strategic Distribution Agreement With Teva Pharmaceuticals Unit
Friday, 13 Sep 2019 

Sept 13 (Reuters) - Intercure Ltd ::SUBSIDIARY CANNDOC ENTERED INTO STRATEGIC DISTRIBUTION AGREEMENT WITH SALOMON, LEVIN, ELSTEIN OWNED BY TEVA PHARMACEUTICALS.S.L.E. WILL DISTRIBUTE CANNDOC'S GMP PRODUCTS TO PHARMA CLIENTS.DISTRIBUTION AGREEMENT IS SET FOR A 3-YEAR TERM AND INCLUDES A MECHANISM FOR AUTOMATIC EXTENSION PERIODS OF TWO YEARS EACH.  Full Article

Teva Canada Announces Approval Of Herzuma
Wednesday, 11 Sep 2019 

Sept 11 (Reuters) - TEVA CANADA::TEVA CANADA ANNOUNCES THE APPROVAL OF HERZUMA®, A BIOSIMILAR TO HERCEPTIN® FOR THE TREATMENT OF ADULT PATIENTS WITH EARLY BREAST CANCER, METASTATIC BREAST CANCER AND METASTATIC GASTRIC CANCER.TEVA CANADA SAYS HEALTH CANADA HAS GRANTED A NOTICE OF COMPLIANCE FOR HERZUMA, BIOSIMILAR TO HERCEPTIN IN CANADA.  Full Article

Allergan Announces Settlement With Two Ohio Plaintiffs In Federal Opioid Litigation
Friday, 30 Aug 2019 

Aug 30 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES SETTLEMENT WITH TWO OHIO PLAINTIFFS IN FEDERAL OPIOID LITIGATION.ALLERGAN PLC - SEEKING INDEMNIFICATION FROM OTHER PARTIES RELATING TO ONE OF ITS PRODUCTS INVOLVED IN LITIGATION. ALLERGAN DOES NOT HAVE LIABILITY FOR GENERIC CLAIMS.ALLERGAN PLC - AS PART OF AGREEMENT, ALLERGAN WILL PAY $1.9 MILLION TO SUMMIT COUNTY, OHIO AND $3.1 MILLION TO CUYAHOGA COUNTY, OHIO.ALLERGAN PLC - CO, U.S. UNITS HAVE REACHED A SETTLEMENT WITH PLAINTIFFS SCHEDULED FOR TRIAL IN OCTOBER 2019 IN FEDERAL OPIOID MULTIDISTRICT LITIGATION.ALLERGAN PLC - SETTLEMENT RESOLVES ALL CLAIMS AGAINST ALLERGAN IN CONNECTION WITH UPCOMING OCTOBER 2019 CLEVELAND TRIAL.ALLERGAN PLC - SETTLEMENT RESOLVES ALL CLAIMS AGAINST ALLERGAN IN CONNECTION WITH UPCOMING OCTOBER 2019 CLEVELAND TRIAL.ALLERGAN PLC - DOES NOT HAVE LIABILITY FOR GENERIC CLAIMS; ALL GENERIC ASSETS WERE SOLD TO TEVA IN 2016.  Full Article

Teva Announces CFO Leadership Transition
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES CFO LEADERSHIP TRANSITION.TEVA PHARMACEUTICAL INDUSTRIES LTD - MICHAEL MCCLELLAN, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER DECIDED TO STEP DOWN FROM HIS ROLE AS CFO.TEVA PHARMACEUTICAL INDUSTRIES LTD - TEVA HAS INITIATED A SEARCH TO IDENTIFY ITS NEXT CFO..TEVA PHARMACEUTICAL INDUSTRIES LTD - MCCLELLAN IS EXPECTED TO REMAIN IN HIS ROLE THROUGH ANNOUNCEMENT OF Q3 RESULTS TO ASSIST WITH A SMOOTH TRANSITION.TEVA PHARMACEUTICAL INDUSTRIES LTD - MCCLELLAN IS EXPECTED TO REMAIN IN HIS ROLE THROUGH ANNOUNCEMENT OF Q3 RESULTS TO ASSIST WITH A SMOOTH TRANSITION..TEVA PHARMACEUTICAL INDUSTRIES LTD - MCCLELLAN TO STEP DOWN FROM HIS ROLE AS CFO DUE TO PERSONAL REASONS.  Full Article

Teva Reports Second Quarter 2019 Financial Results
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.60.Q2 GAAP LOSS PER SHARE $0.63.Q2 REVENUE $4.3 BILLION.FULL YEAR 2019 REVENUES AND EPS GUIDANCE REAFFIRMED.DURING Q2, PORTFOLIO OPTIMIZATION AND NEW LAUNCHES STABILIZED OUR NORTH AMERICAN GENERICS BUSINESS.COPAXONE PERFORMED ABOVE EXPECTATIONS AND AUSTEDO ACHIEVED A VERY STRONG GROWTH RATE IN QUARTER.TEVA PHARMACEUTICAL - SPEND BASE REDUCTION OF $2.7 BILLION SINCE INITIATION OF RESTRUCTURING PLAN IN 2018; ON-TRACK TO ACHIEVE $3.0 BILLION BY END OF 2019.IN Q2 OF 2019, WE RECOGNIZED A TAX BENEFIT OF $179 MILLION, OR 21%, ON PRE-TAX LOSS OF $850 MILLION.INCURRED LEGAL SETTLEMENTS AND LOSS CONTINGENCIES OF $646 MILLION IN QUARTER.AS OF JUNE 30, 2019, OUR DEBT WAS $28,726 MILLION, COMPARED TO $28,624 MILLION AS OF MARCH 31, 2019.TEVA PHARMACEUTICAL INDUSTRIES - NON-GAAP EPS FOR Q2 WAS ADJUSTED TO EXCLUDE IMPAIRMENT OF LONG-LIVED ASSETS OF $609 MILLION.TEVA PHARMACEUTICAL - REVENUE FROM NORTH AMERICA SEGMENT IN Q2 OF 2019 WERE $2,071 MILLION, A DECREASE OF $192 MILLION, OR 8%, COMPARED TO Q2 OF 2018.TEVA PHARMACEUTICAL - GENERIC PRODUCTS REVENUES IN NORTH AMERICA SEGMENT IN Q2 OF 2019 WERE $946 MILLION FLAT COMPARED TO Q2 OF 2018.TEVA PHARMACEUTICAL - COPAXONE REVENUES IN NORTH AMERICA SEGMENT IN Q2 OF 2019 DECREASED BY 41% TO $274 MILLION, COMPARED TO Q2 OF 2018.  Full Article

Bausch Says To Resolve Outstanding Apriso Intellectual Property Litigation With Teva Pharmaceuticals USA
Thursday, 1 Aug 2019 

July 31 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH PROVIDES APRISO® INTELLECTUAL PROPERTY LITIGATION UPDATE.BAUSCH HEALTH COMPANIES INC - BAUSCH HEALTH WILL NOT MAKE ANY FINANCIAL PAYMENTS OR OTHER TRANSFERS OF VALUE AS PART OF AGREEMENT.BAUSCH HEALTH COMPANIES INC - HAVE AGREED TO RESOLVE OUTSTANDING INTELLECTUAL PROPERTY LITIGATION WITH TEVA PHARMACEUTICALS USA, INC.BAUSCH HEALTH - PARTIES AGREED TO DISMISS ALL LITIGATION RELATED TO APRISO, INTELLECTUAL PROPERTY PROTECTING APRISO WILL REMAIN INTACT AND ENFORCEABLE.BAUSCH HEALTH COMPANIES INC - INTELLECTUAL PROPERTY LITIGATION IS REGARDING APRISO (MESALAMINE) EXTENDED-RELEASE CAPSULES 0.375G.BAUSCH HEALTH COMPANIES INC - ALSO AMENDED ITS PRIOR SUB-LICENSE AGREEMENT WITH LUPIN PHARMACEUTICALS, INC.BAUSCH HEALTH -UNDER TERMS, SALIX TO GRANT TEVA NON-EXCLUSIVE LICENSE EFFECTIVE OCT. 1, 2021 TO SALIX INTELLECTUAL PROPERTY RELATING TO APRISO IN U.S..  Full Article

IONTAS Announces New Antibody Optimisation Agreement With Teva Pharmaceuticals
Monday, 29 Jul 2019 

July 29 (Reuters) - IONTAS Limited::IONTAS LIMITED - CO ANNOUNCES NEW ANTIBODY OPTIMISATION AGREEMENT WITH TEVA PHARMACEUTICALS.IONTAS LIMITED -CO WILL INITIALLY APPLY PROPRIETARY TECHNOLOGIES TO PROVIDE TEVA WITH A PANEL OF OPTIMISED ANTIBODIES AGAINST A DEFINED TARGET.IONTAS - TEVA WILL HAVE OPTION TO ENTER INTO FURTHER OPTIMISATION PROGRAMMES IN FUTURE.  Full Article

Teva Announces FDA Approval Of Airduo Digihaler Inhalation Powder
Monday, 15 Jul 2019 

July 15 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES FDA APPROVAL OF AIRDUO® DIGIHALER™ (FLUTICASONE PROPIONATE 113 MCG AND SALMETEROL 14 MCG) INHALATION POWDER.TEVA PHARMACEUTICAL INDUSTRIES LTD - AIRDUO DIGIHALER IS EXPECTED TO BECOME COMMERCIALLY AVAILABLE TO PATIENTS BY PRESCRIPTION IN 2020.  Full Article

UPDATE 6-Opioid settlement talks fail, landmark trial expected Monday

CLEVELAND, Oct 18 A landmark trial over the U.S. opioid epidemic is on track to begin on Monday after drug companies and local governments failed to agree on a settlement on Friday that had been expected to be valued at around $50 billion.